Drug profile · INN
zanidatamab
ZIIHERA
zanidatamab (ZIIHERA) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Jazz Pharmaceuticals Ireland Limited.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01FD07
Patents linked 0
Pipeline programs 13
News articles 0
Drug details — zanidatamab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 13
- Data quality
- 0.89
Quick answer
zanidatamab (ZIIHERA) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Jazz Pharmaceuticals Ireland Limited.
Key facts
INN zanidatamab
Brand ZIIHERA
Mechanism Receptor protein-tyrosine kinase erbB-2 inhibitor
Target Receptor tyrosine-protein kinase erbB-2
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FD07
Originator Jazz Pharmaceuticals Ireland Limited
Mechanism of action
Receptor protein-tyrosine kinase erbB-2 inhibitor
Primary target: Receptor tyrosine-protein kinase erbB-2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is zanidatamab?
zanidatamab (ZIIHERA) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Jazz Pharmaceuticals Ireland Limited.
What is the brand name for zanidatamab?
ZIIHERA is a marketed brand name for zanidatamab. Check FDA Drugs@FDA for the current US label holder and prescribing information.